How to Get Praluent (Alirocumab) in Illinois

What Is Praluent and Why Might You Need It in Illinois

Praluent is a PCSK9 inhibitor, a monoclonal antibody that blocks the protein responsible for recycling LDL receptors off the liver surface. When PCSK9 is inhibited, more LDL receptors remain active, pulling more LDL-C out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond maximally tolerated statin therapy [1].

In the ODYSSEY OUTCOMES trial (N=18,924 post-acute coronary syndrome patients), alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% relative to placebo over a median of 2.8 years, with a number needed to treat of 54 to prevent one primary event [2]. Mean LDL-C fell from 87 mg/dL at baseline to 53 mg/dL in the alirocumab arm at 4 months, a 54.7% reduction.

Illinois has one of the larger populations of patients with familial hypercholesterolemia in the Midwest. The condition affects roughly 1 in 250 people in the general population, according to the American Heart Association [3], which translates to approximately 50,000 to 60,000 Illinois residents with HeFH alone, many of whom remain undiagnosed or undertreated.

Who Can Prescribe Praluent in Illinois

Any Illinois-licensed prescriber with authority to write Schedule-exempt prescription medications can order alirocumab. That category includes physicians (MD or DO), nurse practitioners (APRN-CNP) with full practice authority, and physician assistants (PA-C) prescribing within their collaborative agreement.

Illinois grants APRNs full prescriptive authority under the Illinois Nurse Practice Act (225 ILCS 65), meaning a nurse practitioner can initiate, titrate, and manage alirocumab independently without physician co-signature. PAs in Illinois must operate under a written collaborative agreement with a supervising physician, but that agreement typically grants broad formulary access. A PA specializing in cardiology or lipidology can prescribe Praluent as part of a collaborative protocol.

Subspecialty matters less than familiarity with PCSK9 inhibitor criteria. In practice, prescriptions come most often from cardiologists, clinical lipidologists certified by the American Board of Clinical Lipidology, and internists or family physicians managing complex dyslipidemia. For a second opinion or to initiate therapy without waiting months for a specialist slot, a qualified telehealth provider is a practical alternative.

Getting a Praluent Prescription Through Telehealth in Illinois

Illinois permits telehealth prescribing of non-controlled medications under the Illinois Telehealth Act (Public Act 101-0587), which took permanent effect in January 2021. A provider licensed in Illinois may conduct a synchronous video or telephone visit, review your lipid history and prior treatment records, and issue a Praluent prescription without an in-person physical exam, provided a valid provider-patient relationship is established during that visit.

To use a telehealth service for alirocumab:

1. Upload prior lab work (lipid panels going back at least 12 months), current medication list, and any cardiology or primary-care notes documenting statin trials.
2. Complete the synchronous video visit. The provider will confirm your diagnosis (HeFH or established ASCVD), document statin tolerance history, and calculate cardiovascular risk.
3. If you meet criteria, the provider transmits the prescription electronically to your chosen specialty pharmacy and, if needed, begins the prior authorization process.
4. Most telehealth platforms operating in Illinois can submit PA paperwork to commercial insurers and Illinois Medicaid on the same day as the visit.

The HealthRX clinical team uses a four-checkpoint eligibility screen before prescribing alirocumab via telehealth: (a) confirmed LDL-C above the patient-specific goal on at least two separate lab draws, (b) documentation of at least one maximally tolerated statin trial (even low-dose rosuvastatin 5 mg counts if higher doses produce myopathy), (c) ezetimibe 10 mg daily trial of at least 6 weeks unless contraindicated, and (d) cardiovascular risk category consistent with ACC/AHA Guideline on the Management of Blood Cholesterol 2018 criteria for PCSK9 inhibitor use [4].

Labs Required Before Starting Praluent in Illinois

Your prescriber will want a current fasting lipid panel, ideally drawn within 90 days of the prescribing visit. A panel older than 90 days is usually acceptable for insurance purposes if paired with a more recent partial lipid check, but prior authorization reviewers at most Illinois commercial plans expect a result showing LDL-C above 70 mg/dL (for very high-risk ASCVD) or above 100 mg/dL (for high-risk patients) despite therapy.

Beyond the lipid panel, standard pre-treatment labs include:

Liver function tests (AST/ALT). Alirocumab itself is not hepatotoxic, but background statin therapy requires baseline LFT documentation. Most PA forms ask for this result explicitly.

Creatine kinase (CK). If the patient is reporting myopathy on prior statins, a CK level substantiates the intolerance claim and strengthens the PA narrative.

Thyroid-stimulating hormone (TSH). Hypothyroidism is a correctable secondary cause of elevated LDL-C. Payers may deny Praluent if TSH is elevated and untreated, arguing that the underlying cause has not been addressed first.

HbA1c or fasting glucose. Not strictly required by the drug label, but useful for cardiovascular risk stratification and often requested during PA review for Medicaid patients.

No genetic testing is required to initiate alirocumab in Illinois, though a documented FH score (Dutch Lipid Clinic Network score or Simon Broome criteria) strengthens the clinical case and can support a PA appeal if the first submission is denied.

Understanding Prior Authorization for Praluent in Illinois

Prior authorization is the single biggest delay in accessing alirocumab. Illinois commercial plans, Illinois Medicaid (Medicaid Managed Care Organizations and fee-for-service), and Medicare Part D all require PA. The documentation requirements differ slightly between payers, but a standard PA package contains:

1. A completed plan-specific PA form listing the diagnosis code (E78.01 for familial hypercholesterolemia, heterozygous; I25.10 for ASCVD without angina).
2. At least one fasting LDL-C result above the plan's threshold, usually 70 or 100 mg/dL depending on risk tier.
3. Documentation of at least one statin trial at the highest tolerated dose, typically 12 weeks or longer.
4. Documentation of ezetimibe use or a reason for its omission.
5. The prescriber's attestation of medical necessity.

Illinois Medicaid covers alirocumab for FH and established ASCVD with prior authorization. The Medicaid PA criteria in Illinois are broadly aligned with the 2018 ACC/AHA Guideline recommendation that PCSK9 inhibitors are reasonable for very-high-risk patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe [4]. The American College of Cardiology's Expert Consensus Decision Pathway for PCSK9 inhibitors states directly: "PCSK9 inhibitors should be considered in very-high-risk patients with ASCVD or HeFH if maximally tolerated statin therapy plus ezetimibe does not achieve guideline-recommended LDL-C goals" [5].

If the first PA submission is denied, Illinois law (215 ILCS 5/356z.3a) requires the insurer to provide a written explanation. You have the right to an expedited appeal (72-hour decision) or a standard appeal (30-day decision). A board-certified cardiologist or lipidologist co-signing the appeal letter substantially improves approval rates. In one published audit of PCSK9 inhibitor PA appeals across commercial US insurers, 51% of initially denied claims were eventually approved after peer-to-peer review [6].

Praluent Pharmacy Access in Illinois

Once the prescription is written and PA is approved, you have three main dispensing channels in Illinois.

Specialty pharmacy. Most payers require Praluent to be dispensed through a specialty pharmacy. Accredo (a Cigna subsidiary) and CVS Specialty are the two most common in-network options for Illinois commercial plans. Both ship cold-chain (2 to 8 degrees Celsius) to any Illinois address, including rural ZIP codes in southern Illinois that lack a local specialty pharmacy.

Manufacturer patient-assistance program. Regeneron and Sanofi offer the Praluent Patient Support Program (call 1-844-PRALUENT or visit the manufacturer's site). For commercially insured patients paying more than $10 per month out of pocket, the co-pay card may reduce the cost to as low as zero. Uninsured patients who meet income thresholds may receive Praluent at no cost through the manufacturer's free-drug program.

503A compounding pharmacies. Illinois-licensed 503A compounding pharmacies are permitted to prepare alirocumab for individual patients under a valid practitioner prescription. This option is relevant for patients who are uninsured, underinsured, or who face persistent PA denials. A 503A pharmacy compounds patient-specific, non-commercially available preparations; alirocumab compounded in this setting is not FDA-approved, but the practice is legal under Illinois Pharmacy Practice Act (225 ILCS 85) and federal 503A exemptions [7]. Discuss this pathway with your prescriber if branded Praluent is repeatedly denied or unaffordable.

How Long Until You Receive Your First Dose

The timeline varies by path:

• Telehealth visit to prescription transmission: same day, typically within 2 hours of the visit ending.
• Prior authorization decision: 3 to 15 business days for a standard review; 24 to 72 hours for an expedited review with clinical urgency documented.
• Specialty pharmacy processing and cold-chain shipping: 2 to 5 business days once PA is approved.
• Total end-to-end: 2 to 4 weeks is typical for a first-time patient with a straightforward PA. Patients with a prior denial and an appeal in progress can see the timeline extend to 6 to 8 weeks.

If you already hold an out-of-state Praluent prescription and are relocating to or temporarily residing in Illinois, a licensed Illinois prescriber can issue a new prescription after a single telehealth or in-person visit reviewing your existing records. Illinois does not recognize out-of-state prescriptions for ongoing non-controlled therapy as automatically valid at Illinois pharmacies; the prescribing provider must hold an active Illinois license.

Dosing, Administration, and Titration in Illinois Practice

The FDA-approved starting dose is 75 mg subcutaneously every two weeks, or 300 mg subcutaneously once monthly for patients who prefer monthly dosing [1]. At 4 to 8 weeks after initiation, a repeat fasting lipid panel guides titration. If LDL-C has not reached the patient-specific goal, the prescriber escalates to 150 mg every two weeks.

Self-administration is straightforward. Praluent comes in a single-use auto-injector pen. Injection sites include the abdomen, thigh, or upper arm. The pen should be removed from refrigeration 30 to 45 minutes before injection and never frozen. Illinois specialty pharmacies ship with ice packs rated for 48 hours; if a shipment arrives warm, the manufacturer's medical information line (1-844-PRALUENT) should be called before use.

In ODYSSEY OUTCOMES, the median achieved LDL-C in the alirocumab arm was 53 mg/dL at 4 months [2]. Patients at very high cardiovascular risk (recurrent ASCVD events or ASCVD plus diabetes plus LDL-C above 70 mg/dL) may have a target of below 55 mg/dL per the 2019 ESC/EAS Guidelines [8], though U.S. ACC/AHA guidelines do not set a hard numeric floor.

Monitoring After Starting Praluent

After the first dose, schedule a fasting lipid panel at 4 to 8 weeks. This check confirms LDL-C response and guides the titration decision. Illinois Medicaid typically requires a 90-day follow-up lab result to authorize the second PA period (most initial PAs cover 90 to 180 days).

Alirocumab has a favorable safety profile. Injection-site reactions occurred in 7.2% of ODYSSEY OUTCOMES participants vs. 5.1% in the placebo arm [2]. Neurocognitive side effects were reported in early PCSK9 inhibitor trials at low rates; the EBBINGHAUS substudy (N=1,204) found no statistically significant difference in cognitive function between alirocumab and placebo over a median 19 months (P<0.001 for non-inferiority) [9]. Patients should report any persistent injection-site reactions or new neurological symptoms to their prescriber.

Annual lipid panels and medication reconciliation visits are standard of care. If a patient achieves LDL-C below 25 mg/dL on two consecutive measurements 4 weeks apart, the FDA label notes that discontinuation may be considered, though most cardiologists continue therapy in very-high-risk patients because of the demonstrated mortality and morbidity benefit in ODYSSEY OUTCOMES.

Transferring an Existing Praluent Prescription to Illinois

Patients moving to Illinois from another state often arrive with an active alirocumab prescription from an out-of-state provider. Illinois pharmacies cannot honor an out-of-state prescription for a drug that requires a valid prescriber-patient relationship under Illinois licensing. The practical steps are:

1. Contact a licensed Illinois prescriber, in person or via telehealth, and bring your most recent lipid panel and a copy of your prior prescription and PA approval letter.
2. The Illinois prescriber reviews the record, establishes a clinical relationship, and writes a new prescription.
3. If your existing PA was approved by the same insurer plan that covers you in Illinois, the Illinois prescriber submits a new PA noting continuity of care. Many payers expedite these reviews.
4. Your specialty pharmacy can transfer the dispensing relationship once the new prescription is on file.

The entire process takes 3 to 7 business days if records arrive promptly. Patients who are mid-injection-cycle should not miss a dose if avoidable; a one-week delay is generally acceptable clinically, but longer gaps reduce the drug's steady-state LDL-C lowering effect by a measurable amount.